Characterization of a dual BET/HDAC inhibitor for treatment of pancreatic ductal adenocarcinoma.
Zhang X, Zegar T, Weiser T, Hamdan FH, Berger BT, Lucas R, Balourdas DI, Ladigan S, Cheung PF, Liffers ST, Trajkovic-Arsic M, Scheffler B, Joerger AC, Hahn SA, Johnsen SA, Knapp S, Siveke JT.
Zhang X, et al. Among authors: lucas r.
Int J Cancer. 2020 Nov 15;147(10):2847-2861. doi: 10.1002/ijc.33137. Epub 2020 Jun 29.
Int J Cancer. 2020.
PMID: 32599645